Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
Authors:
- 13 June 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (10) , 943-955
Abstract
Guselkumab is an IL-23 inhibitor widely used for the treatment of moderate-to-severe plaque psoriasis. Our study aimed to characterize the profile of adverse events (AEs) associated with guselkumab from the FDA adverse event reporting system (FAERS). Disproportionality analysis including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms were used to assess the signals of guselkumab related AE. A total of 22,950,014 reports were collected from the FAERS database, of which 24,312 reports regarding guselkumab as the 'primary suspected (PS)' AEs were identified. AEs induced by guselkumab were distributed in 27 organ systems. In this study, 205 significant disproportionality preferred terms (PTs) that matched four algorithms simultaneously were obtained for analysis. Unexpected significant AEs such as onychomadesis, malignant melanoma in situ, endometrial cancer, and erectile dysfunction were observed. The clinical observed AEs, along with potential new AE signals associated with guselkumab were identified based on the analysis of FAERS data, which could provide valuable evidence for clinical monitoring, risk identification, and further safety studies of identification.Keywords
Funding Information
- the national key Research and Development Program of China (2020YFC2005506)
- Key Research and Development Program of Science and Technology Department of Sichuan Province (2019YFS0514)
This publication has 39 references indexed in Scilit:
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systemsNutrition, Metabolism and Cardiovascular Diseases, 2018
- IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinomaScientific Reports, 2018
- Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III TrialsAnnals of Pharmacotherapy, 2017
- Psoriasis pathogenesis and the development of novel targeted immune therapiesJournal of Allergy and Clinical Immunology, 2017
- Guselkumab: First Global ApprovalDrugs, 2017
- Guselkumab for the Treatment of Psoriasis: A Review of Phase III TrialsDermatology and Therapy, 2017
- Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trialBMC Dermatology, 2015
- Liver enzymes, metabolomics and genome-wide association studies: From systems biology to the personalized medicineWorld Journal of Gastroenterology, 2015
- Choosing Thresholds for Statistical Signal Detection with the Proportional Reporting RatioDrug Safety, 2013
- Women encounter ADRs more often than do menEuropean Journal of Clinical Pharmacology, 2008